Merck Rotavirus Vaccine Has Low Risk Of Intussusception, FDA Review Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Discrepancies in reports of follow-up time prevent the agency from reaching a conclusion on RotaTeq’s efficacy.